Another life-saving Covid treatment discovered
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 29, 2022
SUNDAY, MAY 29, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Another life-saving Covid treatment discovered

Coronavirus chronicle

TBS Report
16 June, 2021, 10:15 am
Last modified: 16 June, 2021, 02:19 pm

Related News

  • Patients opting to delay crucial treatment amid rising costs
  • Bangladesh reports 28 new Covid cases in 24hrs
  • Bangladesh logs 30 new Covid cases in 24hrs
  • 34 Covid cases reported in 24 hours
  • Beijing ramps up Covid quarantine, Shanghai residents decry uneven rules

Another life-saving Covid treatment discovered

Results have shown that a potent intravenous infusion of antibodies to neutralise the virus can cure one of every three patients battling Covid-19 in the hospitals, reports BBC.

TBS Report
16 June, 2021, 10:15 am
Last modified: 16 June, 2021, 02:19 pm
Photo: Collected
Photo: Collected

It's been a year since it was revealed that a cheap steroid was capable of preventing Covid Deaths. However, recently, researchers have discovered another life-saving therapy. 

Results have shown that a potent intravenous infusion of antibodies to neutralise the virus can cure one of every three patients battling Covid-19 in the hospitals, reports BBC. 

Experts claim that for every 100 patients treated, it is expected to at least save six lives. 

However, it is to be noted that those who have already been given and are producing antibodies of their own to fight the virus are not eligible for the treatment which can cost anywhere from £1,000 to £2,000.

Kimberley Featherstone, 37, who received the treatment during the trial, said: "I feel very lucky that the trial was up and running by the time I was taken to hospital with Covid-19 and I was able to receive this ground-breaking treatment.

 "I'm happy that by participating I played a part in finding out this treatment is successful."

 This monoclonal antibody treatment is said to bind itself to the virus and prevent it from infecting cells and replicating.

 In the trial, which included nearly 1,000 UK hospital patients, it significantly reduced the:

risk of death

length of hospital stay, by four days on average

likelihood of needing a ventilator to breathe

 Joint chief investigator Sir Martin Landray said: "Giving them this combination of two antibodies by an intravenous infusion then actually reduces their chances of dying by a fifth.

"What we found is nowhere we can use an antiviral treatment, in this case, these antibodies, in patients who have got a one in three chance of dying untreated and we can reduce that risk for them."

 The treatment was given in addition to the anti-inflammatory steroid drug dexamethasone, which itself cuts death risk by up to a third for the sickest Covid patients.

Sir Peter Horby, the other chief investigator, said there had been great uncertainty about whether antibody therapies were the right approach when some other studies had found no benefit.

 Using blood plasma from recovered patients - which contains antibodies that should recognise and fight the virus - has not proved effective as a Covid therapy, for example.

But the antibody treatment used in the Recovery trial contains large doses of two specific antibodies, made in the lab, that are good at latching on to the pandemic virus.

Sir Peter said: "It is wonderful to learn that even in advanced Covid-19 disease, targeting the virus can reduce mortality in patients who have failed to mount an antibody response of their own."

Top News

Covid -19 / treatment

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Patients opting to delay crucial treatment amid rising costs
    Patients opting to delay crucial treatment amid rising costs
  • Bankers unhappy with uniform exchange rate
    Bankers unhappy with uniform exchange rate
  • Photo: PID
    Brand Bangladesh as powerful peace promoting country: PM

MOST VIEWED

  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Shanghai takes further steps towards reopening, Beijing eases Covid curbs
  • Photo: Collected
    US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    'Tomorrow will be better': Shanghai inches towards Covid re-opening
  • North Korea says new fever cases under 100,000 as virus fight heats up
    North Korea says new fever cases under 100,000 as virus fight heats up
  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings

Related News

  • Patients opting to delay crucial treatment amid rising costs
  • Bangladesh reports 28 new Covid cases in 24hrs
  • Bangladesh logs 30 new Covid cases in 24hrs
  • 34 Covid cases reported in 24 hours
  • Beijing ramps up Covid quarantine, Shanghai residents decry uneven rules

Features

Aiman R Khan. Illustration: TBS

Why ‘marry your rapist’ court orders are not always what they seem

2h | Thoughts
Photo: Collected

Top 3 The Ordinary products that give extraordinary results

4h | Mode
Photo: Courtesy

KVN Beauty: Channel your inner Bangalee baddie

4h | Mode
CholPori is planning to roll out their platform in schools so teachers can utilise their tools for the classroom. Photo: Courtesy

CholPori: Where learning is practical, fun and inclusive

4h | Panorama

More Videos from TBS

Photo: TBS

Tips to help you become a successful lawyer

5h | Videos
People bid adieu to Abdul Gaffar Chowdhury

People bid adieu to Abdul Gaffar Chowdhury

5h | Videos
Photo: TBS

Harassment over 'indecent clothing': Women gather at Narsingdi railway station to protest, show solidarity

5h | Videos
Attorney General's suggestion to reduce case clutter

Attorney General's suggestion to reduce case clutter

19h | Videos

Most Read

1
Bangladesh Bank GM, DGM’s designation changed
Banking

Bangladesh Bank GM, DGM’s designation changed

2
Corporates go cashless…tax cut on cards
NBR

Corporates go cashless…tax cut on cards

3
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

4
British International Investment (BII) CEO Nick O’Donohoe. Illustration: TBS
Economy

BII to invest $450m in Bangladesh in 5 years

5
Representational image. Picture: Pixabay
Economy

Govt raises regulatory duty to discourage imports of 130 products

6
Photo: Collected
Industry

Spanish recycled cotton producer opens new facility in Bangladesh

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab